The European Medicines Agency said on Tuesday that it has withdrawn the marketing authorisation for Abbvie's hepatitis C drug ...

Axial Spondyloarthritis (axSpA) is a form of arthritis that mainly causes discomfort and inflammation in the spine and ...

AbbVie's dividend growth has slowed, but new drugs are offsetting Humira's decline. The company's debt levels and payout ratio are high, but its shares screen as undervalued. Recent strategic ...

Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward ...

AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection. However, the shares look pricey at the moment. AbbVie is known as ...

The FDA has faulted AbbVie’s promotion of the migraine drug Ubrelvy, calling the company out for an ad featuring Serena Williams that went out of bounds with claims about how quickly the product ...

AbbVie Inc. ’s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its migraine headache medication, according to US regulators. AbbVie’s TV ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other big name stocks. In early April 2024, Goldman Sachs Inc.’s data revealed that short selling ...

In a lawsuit filed Friday, lawyers for AbbVie argued that BeiGene “enticed and encouraged” former AbbVie scientist Huaqing Liu, who’s named as a defendant in the case, to jump ship and share ...

The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims in a TV ad about a migraine pill that features Serena Williams, the third time this year the agency ...

Local pharmaceutical giant AbbVie is suing drug manufacturer BeiGene over allegedly stealing trade secrets to develop a competing cancer drug following the hiring of a longtime AbbVie research ...

BeiGene hired a former longtime senior scientist at AbbVie, and then developed a competing cancer therapy, a lawsuit argues. Separately, a top Merck executive downplayed the impact of a promising ...